HomeArticle

Just now, the AI company of the Nobel laureate has raised 33.3 billion yuan in financing.

智东西2026-11-18 07:46
The total cumulative financing reached 51.3 billion yuan.

Zhidx News, November 17 — Isomorphic Labs, the UK-based AI drug R&D company founded by Nobel laureate and Demis Hassabis, co-founder of Google DeepMind, has just announced the completion of its $5 billion (approx. RMB 33.3 billion) Series C financing, which was oversubscribed.

According to incomplete statistics based on public data, this round of financing has refreshed the company's previous single-round financing record, and may set a new global record for the single-round financing scale in the AI pharmaceutical sector.

▲ Hassabis announces the completion of Series C financing of Isomorphic Labs (Source: X)

In March 2025, Isomorphic Labs announced the completion of its $600 million (approx. RMB 4 billion) first external financing. Last May, the company secured another $2.1 billion (approx. RMB 14 billion) Series B financing, setting a new record for the single financing amount in the global AI pharmaceutical industry at that time. Adding this Series C round, the total publicly disclosed financing amount of Isomorphic Labs has reached $7.7 billion (approx. RMB 51.3 billion).

This round of financing was jointly led by Greenoaks and HSG (Sequoia Capital), with participation from a16z and multiple new investors, while Alphabet continued to make large-scale investments. All existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated in this financing round.

Founded in 2021 and headquartered in London, UK, Isomorphic Labs is mainly engaged in AI-aided new drug design and development. The company plans to use the new funds to upgrade its proprietary drug design engine IsoDDE, expand its self-developed and partnered drug candidate pipelines, and build a globally AI-driven bioengineering infrastructure. The company stated that positive preclinical results have been achieved in its internal oncology and immunology projects as well as cooperative projects, and preparations are underway to advance them into clinical trials.

01.

Founded by Google DeepMind Co-founder

Focusing on AI Drug Design

Incubated by Google DeepMind, Isomorphic Labs is an AI drug R&D company under Google's parent company Alphabet, operating independently for external financing. The company is led by Demis Hassabis, founder and CEO, and Max Jaderberg, President.

Hassabis is the co-founder of Google DeepMind, Chairman of Google DeepMind and Chief Scientist of Alphabet. He won the 2024 Nobel Prize in Chemistry for his research on protein structure prediction with AlphaFold.

▲ Hassabis, Founder and CEO of Isomorphic Labs

Jaderberg holds a doctorate degree from the University of Oxford, and once led the DeepMind Open Learning Research Team. He is a member of Isomorphic Labs' founding team, previously served as Chief AI Officer, led the development of the company's drug design engine and models including AlphaFold 3, and took office as the company's President in January 2026.

Hassabis said that when founding Isomorphic Labs, the team believed that biology could be understood and modeled at the most fundamental molecular level, and AI could significantly accelerate this process.

He also mentioned that Isomorphic Labs' drug design engine is generating molecules with higher precision and speed, and this round of financing will help the team advance their work faster: building fundamental biological models, deepening the understanding of the systematic mechanisms of diseases, and promoting the first batch of therapeutic projects to clinical trials.

02.

AI Drug Design Engine Covers Multiple Therapeutic Areas

Advancing R&D of Multiple Types of Drugs

The core technology of Isomorphic Labs is its proprietary drug design engine IsoDDE. This engine integrates a set of fundamental simulated AI models, covering multiple therapeutic areas and different drug types.

IsoDDE is capable of exploring the vast chemical space, helping R&D teams design, optimize and screen molecules with ideal druggable properties. Isomorphic Labs states that these simulation models are driving prediction results close to experimental accuracy, providing more capabilities for innovative drug R&D.

In addition to simulation models, Isomorphic Labs has also developed proprietary Agents for exploring complex biological systems and conducting reasoning. The company said that the combination of its models and Agents has continuously driven progress in multiple types of candidate drug pipelines. At present, positive preclinical results have been achieved in the company's internal oncology, immunology projects and cooperative projects, laying a foundation for entering the clinical stage.

Max Jaderberg, President of Isomorphic Labs, said that the team can achieve reproducible scientific research progress with the help of models every week, and convert it into better molecular properties, which are expected to be further developed into new drugs. The company's interdisciplinary team brings together machine learning researchers and drug R&D personnel, and is trying to solve complex biological problems that have been stagnant for decades.

After this round of financing, Isomorphic Labs will continue to improve IsoDDE, and explore new biological fields with more advanced models.

The company also plans to build a partner ecosystem to deepen the understanding of disease occurrence mechanisms, so as to support the development of new therapeutic drug categories. At the same time, Isomorphic Labs will build a global bioengineering infrastructure, as well as a scalable, AI-centered translational research and clinical development system to support candidate drugs entering clinical trials.

03.

Conclusion: After the Huge Financing

Clinical Verification Becomes the Key

The use of this financing has extended from model R&D to drug pipelines, translational research and clinical development infrastructure. For Isomorphic Labs, how to convert its computational prediction and molecular design capabilities into candidate drugs that can enter clinical practice is an important task in the next stage.

At present, most of Isomorphic Labs' major achievements are in the preclinical stage. As the first batch of projects advance to clinical trials, the safety, effectiveness and development progress of its candidate drugs will become an important basis for verifying the capabilities of AI drug design.

Sources: Isomorphic Labs, X

This article is from the WeChat Official Account "Zhidx", written by Yang Jingli, edited by Li Shuiqing, and published by 36Kr with authorization.